The American Journal of Medicine
Volume 122, Issue 1 , Pages 53-61 , January 2009

Long-term C-Reactive Protein Variability and Prediction of Metabolic Risk

  • Ting-hsu Chen, MD

      Affiliations

    • The Framingham Heart Study and Boston University School of Medicine, Framingham, Mass
    • ,
  • Philimon Gona, PhD

      Affiliations

    • The Framingham Heart Study and Boston University School of Medicine, Framingham, Mass
    • Department of Mathematics and Statistics, Boston University, Boston, Mass
    • ,
  • Patrice A. Sutherland, BS

      Affiliations

    • The Framingham Heart Study and Boston University School of Medicine, Framingham, Mass
    • ,
  • Emelia J. Benjamin, MD, ScM

      Affiliations

    • The Framingham Heart Study and Boston University School of Medicine, Framingham, Mass
    • Preventive Medicine and Cardiology Sections, Boston University School of Medicine, Boston, Mass
    • Department of Epidemiology, Boston University School of Public Health, Boston, Mass
    • ,
  • Peter W.F. Wilson, MD

      Affiliations

    • EPICORE, Emory University School of Medicine, Atlanta, Ga
    • ,
  • Martin G. Larson, ScD

      Affiliations

    • The Framingham Heart Study and Boston University School of Medicine, Framingham, Mass
    • Department of Mathematics and Statistics, Boston University, Boston, Mass
    • ,
  • Ramachandran S. Vasan, MD

      Affiliations

    • The Framingham Heart Study and Boston University School of Medicine, Framingham, Mass
    • Preventive Medicine and Cardiology Sections, Boston University School of Medicine, Boston, Mass
    • ,
  • Sander J. Robins, MD

      Affiliations

    • The Framingham Heart Study and Boston University School of Medicine, Framingham, Mass
    • Corresponding Author InformationRequests for reprints should be addressed to Sander J. Robins, MD, Framingham Heart Study, 73 Mount Wayte Avenue, Suite 2, Framingham, MA 01702-5803

References 

  1. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391–397
  2. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–334
  3. Hu FB, Meigs JB, Li TY, et al. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004;53:693–700
  4. Pearson TA, Mensah GA, Alexander R, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511
  5. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49:2129–2138
  6. de Maat MP, de Bart AC, Hennis BC, et al. Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol. 1996;16:1156–1162
  7. Sakkinen PA, Macy EM, Callas PW, et al. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol. 1999;149:261–267
  8. Ockene IS, Matthews CE, Rifai N, et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem. 2001;47:444–450
  9. Kayaba K, Ishikawa S, Gotoh T, et al. Five-year intra-individual variability in C-reactive protein levels in a Japanese population-based study: the Jichi Medical School Cohort Study at Yamato, 1993-1998. Jpn Circ J. 2000;64:303–308
  10. Kannel WB, Feinleib M, McNamara PM, et al. An investigation of coronary heart disease in families (The Framingham offspring study). Am J Epidemiol. 1979;110:281–290
  11. Cupples LA, D'Agostino RB, Kiely D. The Framingham Heart Study, Section 35 (An Epidemiological Investigation of Cardiovascular Disease Survival Following Cardiovascular Events: 30 Year Follow-up). Bethesda, MD: National Heart, Lung and Blood Institute; 1988;
  12. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome (Report of the National Heart, Lung, and Blood Institute/American Heart association conference on scientific issues related to definition). Circulation. 2004;109:433–438
  13. Wilson PW, Garrison RJ, Castelli WP, et al. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol. 1980;46:649–654
  14. Abel LL, Levy BB, Brodie BB, Kendall FE. A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem. 1952;195:357–366
  15. Manual of Laboratory Operations: Lipid Research Clinics Program, Lipid and Lipoprotein Analysis. 2 ed.. Washington, DC: National Institutes of Health, US Dept of Health and Human Services; 1982;
  16. Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem. 2003;49:1258–1271
  17. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA. 2002;288:980–987
  18. Silvestri A, Gebara O, Vitale C, et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation. 2003;107:3165–3169
  19. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103:1933–1935
  20. Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL Study. Circulation. 2003;108:1560–1566
  21. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414–419
  22. Ingelsson E, Pencina MJ, Tofler GH, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation. 2007;116:984–992
  23. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol. 1999;19:972–978
  24. Hak AE, Stehouwer CD, Bots ML, et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol. 1999;19:1986–1991
  25. McLaughlin T, Abbasi F, Lamendola C, et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation. 2002;106:2908–2912
  26. Rutter MK, Meigs JB, Sullivan LM, et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004;110:380–385
  27. Ridker PM, Wilson PWF, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation. 2004;109:2818–2825
  28. Ford ES, Giles WH, Myers GL, Mannino DM. Population distribution of high-sensitivity C-reactive protein among US men: findings from National Health and Nutrition Examination Survey 1999-2000. Clin Chem. 2003;49:686–690
  29. Wener MH, Daum PR, McQuillan GM. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. J Rheumatol. 2000;27:2351–2359

 Funding Source: This work was supported through the following grants: 1R01-HL64753, 1R01 HL076784, 1R01-AG028321 (E.J.B.); 2K24HL04334 (R.S.V.); R01 HL073272 (P.W.F.W.); National Institutes of Health/National Heart, Lung, and Blood Institute Contract N01-HC-25195.

 Conflict of Interest: None of the authors have any conflicts of interest to disclose.

 Authorship: All authors had access to all data and made substantial contributions to writing this article.

PII: S0002-9343(08)00898-X

doi: 10.1016/j.amjmed.2008.08.023

The American Journal of Medicine
Volume 122, Issue 1 , Pages 53-61 , January 2009

Article Tools